BioSpace News Archive

AirXpanders today that its AeroForm System earned a Best of What’s New award in the health category by Popular Science, the world’s largest science and technology magazine.

FluGen Inc., announced today that it has been awarded a grant of $14.4 million through the DOD’s Congressionally Directed Medical Research Programs Peer Reviewed Medical Research Program’s (PRMRP) mechanism to conduct clinical challenge-studies against mismatched influenza strains with its lead universal flu vaccine, RedeeFlu.

Quad Technologies, a leader in cell and gene therapy bioprocessing reagents, announced today the U.S. Patent and Trademark Office has awarded the company a new U.S. Patent, No. 9,790,467, titled “Methods and Compositions for activation or expansion of T lymphocytes”.

Entatio today announced the release of Entatio for Pharma, a cloud application built specifically for pharmaceutical and medical device companies to aid in the delivery of highly regulated medical content to physicians through medical conferences and events.

Life Spine, a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spinal disorders today announced the Alpha launch of the SENTRY ALIF Plating System.

The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study’s Principle Investigator.

Lysogene, a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in and presenting at several scientific events in the upcoming weeks.

Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.

Conceivex, maker of The Conception Kit at-home system, today named veteran life sciences industry executive Michael S. Rosen to its Board of Directors.

The NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.